Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Puretech Health Plc ADR (PRTC)

Puretech Health Plc ADR (PRTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 436,232
  • Shares Outstanding, K 24,168
  • Annual Sales, $ 4,830 K
  • Annual Income, $ 27,780 K
  • EBIT $ 0 M
  • EBITDA $ -133 M
  • 60-Month Beta 1.13
  • Price/Sales 84.05
  • Price/Cash Flow 7.04
  • Price/Book 1.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.50 +16.45%
on 11/21/25
18.05 unch
on 12/05/25
+1.05 (+6.18%)
since 11/05/25
3-Month
14.50 +24.48%
on 09/18/25
19.23 -6.14%
on 10/02/25
+1.82 (+11.20%)
since 09/05/25
52-Week
13.30 +35.71%
on 04/10/25
23.69 -23.81%
on 12/06/24
-2.98 (-14.17%)
since 12/05/24

Most Recent Stories

More News
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

LYT-200 demonstrated favorable tolerability and strong efficacy in a heavily pretreated population, both in combination with standard of care and as a monotherapy, supporting advancement toward a potentially...

PRTC.LN : 122.000 (-0.16%)
PRTC : 18.05 (+7.50%)
PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting

LYT-200 continues to demonstrate strong evidence of clinical activity, survival benefit and a highly favorable safety profile in heavily pretreated relapsed/refractory AML patients, both as a monotherapy...

PRTC.LN : 122.000 (-0.16%)
PRTC : 18.05 (+7.50%)
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

Data presented at the CHEST 2025 Annual Meeting highlight deupirfenidone’s differentiated profile and potential to address unmet needs across age groups

PRTC.LN : 122.000 (-0.16%)
PRTC : 18.05 (+7.50%)
Leerink Partners Reaffirms Their Buy Rating on PureTech Health (PRTC)

Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on PureTech Health on September 30. The company’s shares closed yesterday at $19.00.Elevate Your Investing Strategy: Take advantage of...

PRTC : 18.05 (+7.50%)
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

Patients who switched from placebo or pirfenidone to deupirfenidone in the open-label extension study achieved stabilization of lung function with favorable tolerability ...

PRTC.LN : 122.000 (-0.16%)
PRTC : 18.05 (+7.50%)
PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgoâ„¢ (SPT-320) in Healthy Volunteers

GlyphAgo is an oral prodrug of agomelatine, a medicine with established clinical efficacy in generalized anxiety disorder (GAD) GlyphAgo is designed to overcome a key...

PRTC.LN : 122.000 (-0.16%)
PRTC : 18.05 (+7.50%)
PureTech Health plc – Half-Year Report

Achieved meaningful progress toward key value inflection points across our diversified portfolio, with multiple programs advancing into or toward late-stage development ...

PRTC.LN : 122.000 (-0.16%)
PRTC : 18.05 (+7.50%)
VOR : 8.18 (-1.80%)
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF

Deupirfenidone to be advanced by PureTech’s newly launched Founded Entity, Celea Therapeutics

PRTC.LN : 122.000 (-0.16%)
PRTC : 18.05 (+7.50%)
PureTech Health: Notice of Half-Yearly Results

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended June 30, 2025, on Thursday, August 28, 2025. ...

PRTC.LN : 122.000 (-0.16%)
PRTC : 18.05 (+7.50%)
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

VE202 was well tolerated, with no reports of treatment-related serious adverse events Additional analyses from COLLECTiVE202 to be shared...

PRTC.LN : 122.000 (-0.16%)
PRTC : 18.05 (+7.50%)

Business Summary

PureTech Health plc is a clinical-stage biotherapeutics company. It engages in discovering, developing and commercializing medicines for devastating diseases, including inflammatory and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological...

See More

Key Turning Points

3rd Resistance Point 20.77
2nd Resistance Point 19.41
1st Resistance Point 18.73
Last Price 18.05
1st Support Level 16.69
2nd Support Level 15.33
3rd Support Level 14.65

See More

52-Week High 23.69
Fibonacci 61.8% 19.72
Fibonacci 50% 18.50
Last Price 18.05
Fibonacci 38.2% 17.27
52-Week Low 13.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar